47 completed. 47 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 47 | Completed 47 |
| Phase 2 | 6 | Completed 6 |
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects HRS-1301 Tablets, Rosuvastatin Calcium Tablets - Hyperlipidemia | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2025-10-09 | 2026-01-09 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects HRS-1301, HRS-1301 placebo - Hyperlipidemia | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 84 | 2025-03-18 | 2026-09-30 |
| A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects HRS-7249 injection, Placebo - Hyperlipidemia | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 48 | 2024-08-15 | 2025-09-15 |
| Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) - Hyperlipidemia | Phase 1 | Completed | Novartis Pharmaceuticals | 40 | 2021-02-26 | 2025-03-25 |
| Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers ASC41 tablet - Healthy, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 12 | 2020-12-27 | 2024-09-27 |
| Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects ASC 41, ASC 41 Placebo - Overweight and Obesity, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 20 | 2020-12-22 | 2024-09-27 |
| Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects DC371739, Placebo - Hyperlipidemia | Phase 1 | Completed | Guangzhou JOYO Pharma Co., Ltd | 43 | 2020-09-25 | 2025-08-03 |
| The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia SHR-1209, Placebo - Hyperlipidemia | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 110 | 2019-06-20 | 2022-11-30 |
| Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers JLP-1310, Fasted followed by fed, JLP-1310, Fed followed by fasted - Diabetes, Hyperlipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 16 | 2017-08-02 | 2018-03-29 |
| The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers Metformin + Rosuvastatin, JLP-1310 - Diabetes, Hyperlipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 40 | 2017-07-06 | 2018-03-29 |
| Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin Temisartan/Amlodipine+Rosuvastatin, YHP1604 - Hypertension, Hyperlipidemia | Phase 1 | Completed | Yuhan Corporation | 62 | 2017-04-21 | 2019-01-16 |
| Bioequivalence Study of CJ-30061 in Healthy Male Volunteers CJ-30061, Exforge® 5/160mg & Lipitor® 20mg - Hypertension, Hyperlipidemia | Phase 1 | Completed | HK inno.N Corporation | 42 | 2016-09-19 | 2018-09-05 |
| A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin Twynsta 80/5mg, Crestor 20mg - Hypertension, Hyperlipidemia | Phase 1 | Completed | Yuhan Corporation | 60 | 2016-08-01 | 2017-02-01 |
| A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers A: NK-104-CR 8 mg, B: Pitavastatin IR 4 mg, C: Pitavastatin IR 8 mg - Hyperlipidemia | Phase 1 | Completed | Kowa Research Institute, Inc. | 18 | 2015-12-01 | 2016-01-11 |
| A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin - Hypertension, Hyperlipidemia | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 100 | 2015-09-01 | 2016-02-24 |
| A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet Fimasartan/Atorvastatin Combination Tablet, Fimasartan, Atorvastatin - Hypertension, Hyperlipidemia | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 99 | 2015-08-01 | 2016-02-25 |
| The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine Rosuvastatin, Telmisartan/Amlodipine, Rosuvastatin and Telmisartan/Amlodipine - Hypertension, Hyperlipidemia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 41 | 2015-02-01 | 2016-06-24 |
| Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab Evolocumab - Hyperlipidemia, Mixed Dyslipidemia | Phase 1 | Completed | Amgen | 18 | 2014-08-19 | 2022-11-07 |
| Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin Metformin, Rosuvastatin, Metformin and Rosuvastatin - Hyperlipidemia, Diabetes | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 24 | 2014-08-01 | 2018-03-29 |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects K-312 10 mg QD, K-312 25 mg QD, K-312 50 mg QD - Hyperlipidemia | Phase 1 | Completed | Kowa Research Institute, Inc. | 120 | 2014-04-01 | 2016-02-12 |
Showing 20 of 47. Sign in to see all of them.
Hyperlipidemias (47) · Hypertension (14) · Obesity (5) · Diabetes Mellitus (4) · Body Weight (2) · Essential Hypertension (2) · Hypercholesterolemia (2) · Inflammation (2) · Metabolic Syndrome (2) · Motor Activity (2) · Non-alcoholic Fatty Liver Disease (2) · Overweight (2) · Alzheimer Disease (1) · Cardiovascular Diseases (1) · Dementia (1)
Dyslipidemias (47) · Lipid Metabolism Disorders (47) · Metabolic Diseases (47) · Nutritional and Metabolic Diseases (47) · Cardiovascular Diseases (16) · Vascular Diseases (16) · Pathological Conditions, Signs and Symptoms (9) · Glucose Metabolism Disorders (7) · Signs and Symptoms (7) · Nutrition Disorders (6) · Overnutrition (6) · Body Weight (5) · Endocrine System Diseases (4) · Overweight (4) · Hyperinsulinism (3)
Rosuvastatin Calcium (9) · Atorvastatin (6) · Telmisartan (4) · Amlodipine (3) · Metformin (3) · Valsartan (3) · pitavastatin (3) · Ezetimibe (2) · Fatty Acids, Omega-3 (2) · evolocumab (2) · fimasartan (2) · levamlodipine (2) · telmisartan amlodipine combination (2) · ALN-PCS (1) · Amlodipine, Valsartan Drug Combination (1)
Jeil Pharmaceutical Co., Ltd. (4) · Chong Kun Dang Pharmaceutical (3) · Yuhan Corporation (3) · Amgen (2) · Boryung Pharmaceutical Co., Ltd (2) · Gannex Pharma Co., Ltd. (2) · JW Pharmaceutical (2) · Kowa Research Institute, Inc. (2) · Organon and Co (2) · Shandong Suncadia Medicine Co., Ltd. (2) · University of Manitoba (2) · Eli Lilly and Company (1) · Esperion Therapeutics, Inc. (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Guangzhou JOYO Pharma Co., Ltd (1)
South Korea (17) · United States (13) · China (8) · Cameroon (1) · Canada (1) · Japan (1) · United Kingdom (1)
Kyun Seop Bae, MD (2) · Charles H Ballow, Pharm D. (1) · Curtis Rempel, PhD, MBA (1) · Donald I Abrams, MD (1) · Dong-seok Yim, professor (1) · Gary D Foster, PhD (1) · Gary Fulcher, PhD (1) · JaeWook Ko, PhD (1) · Judith Aberg, M.D. (1) · Julius E Oben, PhD (1) · Jung-ryul Kim, MD, Ph.D (1) · Kyung-Sang Yu, M.D., Ph.D., M.B.A. (1) · Kyungsoo Park, MD, Ph.D. (1)
PMID 18068514, PMID 21120461, PMID 21593349, PMID 21831304, PMID 22743313, PMID 23638799, PMID 23706094, PMID 24077434, PMID 25202920, PMID 35039035, PMID 37164838, PMID 40587053
M01RR000334 (1), R21AG023805 (1), R21NR011281 (1), U54DK083912 (1)